The PennZone

CARTHAGE, Mo. - PennZone -- Stratum Nutrition^®, (a business of ESM Technologies), along with our Brazilian partner Ayalla, are pleased to announce that ANVISA, the National Health Surveillance Agency of the Brazilian Ministry of Health, has granted "safety and efficacy as a bioactive substance" pre-market approval of NEM® brand eggshell membrane on January 14, 2021. This approval was the culmination of a multi-year review by ANVISA of NEM's safety and efficacy substantiation, which is required for foods or bioactive substances claims in Brazil.

Sandra de Anselmo, President of Ayalla, said, "NEM is an innovative science-based ingredient approved for the first time by ANVISA in Brazil. We are very proud and excited to introduce such a robust ingredient to the Brazilian market and we are sure it will be a best-selling product in Brazil. We thank our partner, Stratum for the endless support they have given us through the approval process, and we hope to live up to their expectations just the same."

"Brazil marks the 3^rd rigorous regulatory agency review of NEM's safety and efficacy data, following Canadian and Australian approvals in recent years.  "We are extremely gratified to receive approval from ANVISA, as this again validates the substantial scientific portfolio that supports NEM and its health claims.  Brazil is a major market for joint health ingredients and we believe that an innovative, scientifically-backed ingredient like NEM will quickly establish itself as a category leader." said Kevin J. Ruff, Ph.D., MBA, Sr. Director of Scientific & Regulatory Affairs for Stratum Nutrition.

More on The PennZone

• 'Reflections: Enlightening Insights Into the Divine Mystery' — The Latest Book by Philosopher Steven Colborne
• Scott G. Hoy of Hoy Law Earns 11th Consecutive Super Lawyers Selection
• Brother Marcus Unlocks the Vault
• L2 Aviation Selected for U.S. Air Force KC-46 CASPER Multiple Award Contract
• Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH

NEM is one of the few joint health ingredients, and the only eggshell membrane ingredient that is supported by a full portfolio of 16 research studies, including: 4 randomized placebo-controlled trials (2 of which are healthy person trials); 4 open label clinical trials (3 of which were conducted independently); veterinary trials, including one canine RCT; and a wide range of supporting in vitro and in vivo mechanism of action studies.  In addition to subjective endpoints like joint pain and stiffness, recent clinical trials have included objective endpoints via the CTX-II cartilage degradation biomarker, giving the results additional credibility and substantiation.

Stratum is the global leader in eggshell membrane science and technology for joint health with products in over 20 countries. For more information about NEM® and other ingredients, please visit www.stratumnutrition.com.

###

About Stratum Nutrition

Stratum Nutrition^®, a business of ESM Technologies, LLC, sustainably provides world class nutrition ingredient solutions to nutritional product formulators for human and pet health. Stratum offers a portfolio of research-supported, branded ingredients that are progressive, safe and effective, including NEM^® brand eggshell membrane, ESC^® brand eggshell calcium, Ahiflower^® plant-based omegas-3,6,9, Curcumin 95, BioCurc^®, LBiome™ Lactobacillus LB postbiotic, Nataxtin^TM astaxanthin, as well as oral-cavity probiotics, BLIS K12™ and BLIS M18™. These trusted ingredients are relied upon by consumers internationally. Visit www.stratumnutrition.com for more information.

More on The PennZone

• Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
• KeysCaribbean Resorts Offer Savings On Summer Vacations Now Through Aug. 31
• Crossroads4Hope Announces The Lipschutz Women's Fund
• AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
• 91 Per Cent of Enterprises Will Increase AI Spending. Most Can't See the Cost — or the Risk!